Monopar Therapeutics Inc Stock Price, News & Analysis

Monopar Therapeutics (MNPR) and NorthStar Medical Radioisotopes have filed a provisional patent for a radiotherapeutic combining Monopar's MNPR-101 antibody with Actinium-225. The Radio-Immuno-Therapeutic (RIT) shows 98% radiochemical purity, indicating potential as an effective treatment for certain cancers and severe COVID-19.

This development may also allow for more efficient production with reduced material use, thus improving supply chain logistics. If granted, the patent could significantly enhance MNPR-101’s patent estate.

Monopar Therapeutics Inc. (MNPR) and NorthStar Medical Radioisotopes have filed a provisional patent for a new approach to improve the efficacy of Actinium-based radiopharmaceuticals. The patent focuses on using PCTA to enhance binding efficiency of Ac-225 to antibodies, showing nearly 100% binding compared to traditional methods. This innovation could lead to increased efficacy, reduced toxicity, and better manufacturing efficiency. The companies aim to explore development and licensing opportunities for this technology, which holds potential to address challenges in cancer treatment.

Monopar Therapeutics Inc. (Nasdaq: MNPR) announced key updates in their latest press release dated May 13, 2021. The company reported the first patient dosed in the Phase 2b/3 VOICE clinical trial for Validive, aimed at preventing severe oral mucositis in cancer patients. They also received patent allowances for Validive and a novel family of camsirubicin analogs. Financially, Monopar holds $25.7 million in cash, though net losses increased to $1.9 million in Q1 2021.

Monopar Therapeutics (Nasdaq: MNPR) announced the publication of a peer-reviewed study demonstrating the potential of its uPA antibody fragment for imaging triple-negative breast cancer. The study suggests that this technology could facilitate rapid PET imaging to identify and monitor uPA overexpression in tumors, which is crucial for treatment decisions. The company is optimistic about leveraging its panel of uPA-targeted antibodies for cancer imaging and treatment development.

Monopar Therapeutics (Nasdaq: MNPR) recently announced key developments and financial results for Q4 and full-year 2020. The company commenced the Phase 2b/3 VOICE clinical trial for Validive, aimed at preventing severe oral mucositis in oropharyngeal cancer patients. A Phase 2 trial for camsirubicin is set to begin in Q2 2021, evaluating its effectiveness against doxorubicin. The company reported a net loss of $6.3 million for 2020, showing an increase from $4.2 million in 2019, with cash reserves of $16.7 million to support operations at least through March 2022.

Monopar Therapeutics Inc. (Nasdaq: MNPR) has announced a collaboration with Andrew Cittadine to explore strategic options for MNPR-101 as an imaging agent in bladder cancer surgeries. Cittadine, a seasoned entrepreneur in medtech, brings a wealth of experience in oncology diagnostics. The partnership aims to leverage MNPR-101's potential following promising early data published in the European Journal of Cancer. The company focuses on developing therapeutics that improve the quality of life for cancer patients, including its pipeline products.

Monopar Therapeutics Inc. (Nasdaq: MNPR), a biopharmaceutical company focused on cancer therapeutics, announced upcoming presentations by CEO Chandler D. Robinson at several investor conferences in March. The presentations include:

• H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET.
• 33rd Annual Roth Conference on March 16, 2021, at 12:00 p.m. ET.
• Maxim’s 2021 Emerging Growth Virtual Conference on March 17, 2021, with the timing to be determined.

Monopar develops therapeutics aimed at improving cancer patients' lives.

Monopar Therapeutics (Nasdaq: MNPR) has appointed Laura Kelly as the new Director of Clinical Operations. With extensive experience in clinical research, particularly in oncology, she will oversee the Phase 2b/3 VOICE trial for Validive and other clinical programs. CEO Chandler Robinson emphasized her role is timely given the company's development efforts. Her leadership is expected to enhance clinical trial execution and enrollment. This strategic appointment aims to strengthen Monopar's capabilities in advancing its pipeline for cancer therapies.

Monopar Therapeutics (Nasdaq: MNPR) announced the dosing of the first patient in its Phase 2b/3 VOICE trial for Validive aimed at preventing chemoradiotherapy-induced severe oral mucositis (SOM) in oropharyngeal cancer patients. Validive's formulation allows for easy self-administration and targets a significant unmet need as approximately 40,000 patients in the US suffer from SOM annually. The previous Phase 2 trial indicated a 40% reduction in SOM incidence with Validive. The current trial plans to enroll around 260 patients.